Oral and intravenous administration of nimesulide in the horse: rational dosage regimen from pharmacokinetic and pharmacodynamic data.

The research study objectively explores the use of the anti-inflammatory agent, nimesulide, in horses, an area currently lacking adequate data. It identifies the effective COX selectivity of nimesulide in horses and suggests a suitable dosing schedule while considering the risk of COX-1 inhibition side-effects.

Study Methodology

• The researchers carried out pharmacokinetic studies on the activity of nimesulide in horses. Pharmacokinetics refers to how a drug is absorbed, distributed, metabolized, and ultimately eliminated by the body.
• The subjects were administered nimesulide both orally at 1mg/kg bwt and intravenously at 1.5 mg/kg bwt. Additionally, the study also considered the effects of feeding status on drug bioavailability.
• The study measured plasma protein binding of the drug and its main metabolites, providing insights into how the drug might act within the body.
• Analyses were performed using both compartmental and non-compartmental pharmacokinetic methods. This provided a detailed analysis of the drug’s presence in the body over time.

Findings

• The study suggests that a dosage of 1.5mg/kg bwt (body weight) could produce satisfactory clinical effects. The researchers recommend a dosing interval of 12-24 hours depending on the severity of the condition in the horse.
• However, at this dosage, the concentration of nimesulide in the horse body would exceed the in vitro IC50 for both COX isoforms. The IC50 value is a measurement used in pharmacology to indicate the concentration at which a substance exerts half of its maximal inhibitory effect.
• This implies that nimesulide’s selectivity for inhibiting COX-2 over COX-1 is lost. As a result, this increases the possibility of side effects due to COX-1 inhibition. COX-1 and COX-2 are enzymes known to facilitate the production of prostanoids, including prostaglandins, which are involved in inflammation and pain pathways.

Conclusion and Clinical Implications

• The research concludes that nimesulide may have potential benefits when used in equine care, particularly for its anti-inflammatory effects. However, due to the risk of losing COX-1/COX-2 selectivity and the possible side effects from COX-1 inhibition, the drug should be employed cautiously.
• This study provides a helpful basis for determining a rational dosage of nimesulide for horses, but further research will be necessary to fully understand the drug’s potential effects and risks in equine applications.